Akzo Nobel Pharma In For “Rough Ride” In 2004; Firm Will Rely On Partnering, R&D Investment
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite expected “hit from lower sales” for pharmaceuticals in 2004, Akzo will continue to invest in R&D as “something stable,” company tells analysts. Potential 2004 launches include Organon’s Implanon and Variza, both pending at FDA.
You may also be interested in...
Organon, Pfizer Hope Hot Flashes Will Be Hot Market
Organon's 5HT2-antagonist Org 50018 is in Phase II/III development as an alternative to hormone therapy for treatment of hot flashes. Pfizer also has eyes on the market, licensing a University of Rochester patent that covers use of Lyrica.
Organon, Pfizer Hope Hot Flashes Will Be Hot Market
Organon's 5HT2-antagonist Org 50018 is in Phase II/III development as an alternative to hormone therapy for treatment of hot flashes. Pfizer also has eyes on the market, licensing a University of Rochester patent that covers use of Lyrica.
Organon Pharma Focus Is "Short Term": Strategic Decisions Later
Akzo Nobel wants to "fix pharma first" before it makes any decisions about long-term strategy in Rx sector, company says. Sales of Follistim are being held back by supply problems following shutdown of West Orange, N.J. plant.